Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis

Background: There is still debate whether ribavirin should be added to direct-acting antivirals (DAAs) for the management of treatment-experienced individuals with non-genotype-1 hepatitis C. This study compared the efficacy and safety of adding ribavirin to sofosbuvir-based combinations compared to...

Full description

Saved in:

Bibliographic Details
Main Authors:	Shahd Hamran, Amani A. Al-Rajhi, Kawthar Jasim, Majed A. Al-Theyab, Mohamed Elahtam, Mooza K. Al-Hail, Wadha Al-Fahaidi, Yaman A. Khamis, Yara Dweidri, Abdel-Naser Elzouki, Tawanda Chivese
Format:	Article
Language:	English
Published:	MDPI AG 2025-04-01
Series:	Diseases
Subjects:	hepatitis C virus (HCV) ribavirin (RBV) direct-acting Antivirals (DAAs) HCV genotype sustained virological response (SVR) systematic review and meta-analysis
Online Access:	https://www.mdpi.com/2079-9721/13/5/138
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis

Similar Items